We believe that it is mandatory to extend the analysis of CCDC6 and USP7 protein expression to a larger series of prostate tumor samples in order to strenghten our observations about the joined/combined expression of the two proteins, and to predict the outcome of this tumor following the treatment with the USP7 inhibitors and PARP inhibitors, in combination with genotoxic durgs. This evidence concerns the gene PARP1 and neoplasm.